NCT00080535View on ClinicalTrials.gov

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
LymphomaT-CellCutaneous
Interventions
BIOLOGICAL

LMB-2

30 micrograms/kg every other day (QOD) x 3 every 4 weeks

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00080535 - Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas | Biotech Hunter | Biotech Hunter